(Cassava Sciences) Shares of Cassava Sciences were up more than 18% in premarket after its drug candidate simufilam showed breakthrough for mild to moderate forms of Alzheimer disease.
In an interim analysis, ADAS-Cog11 scores improved by an average of 3.2 points in 12 months from the baseline in the initial 50 study subjects.
Changes in ADAS-Cog scores baseline to the 12th month were independently analyzed by two consulting biostatisticians.
Cassava Sciences now expects to advance simufilam into Phase 3 clinical program in Alzheimer’s disease. The study is on-track during the fourth quarter of this year.
SAVA: NASDAQ is up +13.77%.
